These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 15225731)
1. Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect. Creighton CJ; Ramabadran K; Ciccone PE; Liu J; Orsini MJ; Reitz AB Bioorg Med Chem Lett; 2004 Aug; 14(15):4083-5. PubMed ID: 15225731 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR study of opioid receptor ligands: mono- and bis-indolomorphinans. Li F; Yin C; Chen J; Liu J; Xie X; Zhang A Chem Biol Drug Des; 2009 Oct; 74(4):335-42. PubMed ID: 19691470 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Lester PA; Traynor JR Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. Peng X; Knapp BI; Bidlack JM; Neumeyer JL J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810 [TBL] [Abstract][Full Text] [Related]
14. mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model. Zhao M; Wang JY; Jia H; Tang JS Brain Res; 2006 Mar; 1076(1):68-77. PubMed ID: 16476416 [TBL] [Abstract][Full Text] [Related]
15. Has the sun set on kappa3-opioid receptors? Connor M; Kitchen I Br J Pharmacol; 2006 Feb; 147(4):349-50. PubMed ID: 16402044 [TBL] [Abstract][Full Text] [Related]
16. [Atomoxetine in the treatment of ADHD]. Myhr K Tidsskr Nor Laegeforen; 2006 Feb; 126(4):457-8. PubMed ID: 16477285 [No Abstract] [Full Text] [Related]
17. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295 [TBL] [Abstract][Full Text] [Related]
18. A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability. Park HS; Lee HY; Kim YH; Park JK; Zvartau EE; Lee H Bioorg Med Chem Lett; 2006 Jul; 16(13):3609-13. PubMed ID: 16650985 [TBL] [Abstract][Full Text] [Related]
20. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]